Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Markowitz

Showing results (41-50 of 82) with videos related to

Pageof 9
Sort By:
Bioinformatics (Oxford, England)|November 4, 2021
spatialTIME and iTIME: R package and Shiny application for visualization and analysis of immunofluorescence dataJordan H Creed, Christopher M Wilson, Alex C Soupir, et al.
Journal of Neuro-Oncology|March 9, 2026
Melanoma brain metastases outcomes following nivolumab and relatlimab after ipilimumab and nivolumab progressionVaseem M Khatri, Michael Aboujaoude, Lilit Karapetyan, et al.
Cancer Research|December 5, 2024
spatialGE Is a User-Friendly Web Application That Facilitates Spatial Transcriptomics Data AnalysisOscar E Ospina, Roberto Manjarres-Betancur, Guillermo Gonzalez-Calderon, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 4, 2014
NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformationAnn-Kathrin Eisfeld, Sebastian Schwind, Kevin W Hoag, et al.
Oncotarget|October 27, 2016
The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanomaLorena P Suarez-Kelly, Gregory M Kemper, Megan C Duggan, et al.
Melanoma Research|May 23, 2019
Neuroblastoma RAS viral oncogene homolog mRNA is differentially spliced to give five distinct isoforms: implications for melanoma therapyMegan C Duggan, Kelly Regan-Fendt, Gonzalo N Olaverria Salavaggione, et al.
Frontiers in Immunology|June 30, 2023
Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapyChad Pickering, Paul Aiyetan, Gege Xu, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 10, 2013
A phase I trial of bortezomib and interferon-α-2b in metastatic melanomaJoseph Markowitz, Eric A Luedke, Valerie P Grignol, et al.
JCO Precision Oncology|June 7, 2021
Integrating Somatic and Germline Next-Generation Sequencing Into Routine Clinical Oncology PracticeJ Kevin Hicks, Rachel Howard, Phillip Reisman, et al.
Cancer Immunology, Immunotherapy : CII|February 7, 2019
A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanomaLorena P Suarez-Kelly, Kala M Levine, Thomas E Olencki, et al.
Pageof 9

Showing results (41-50 of 82) with videos related to

Sort By:
Pageof 9
Bioinformatics (Oxford, England)|November 4, 2021
spatialTIME and iTIME: R package and Shiny application for visualization and analysis of immunofluorescence dataJordan H Creed, Christopher M Wilson, Alex C Soupir, et al.
Journal of Neuro-Oncology|March 9, 2026
Melanoma brain metastases outcomes following nivolumab and relatlimab after ipilimumab and nivolumab progressionVaseem M Khatri, Michael Aboujaoude, Lilit Karapetyan, et al.
Cancer Research|December 5, 2024
spatialGE Is a User-Friendly Web Application That Facilitates Spatial Transcriptomics Data AnalysisOscar E Ospina, Roberto Manjarres-Betancur, Guillermo Gonzalez-Calderon, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 4, 2014
NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformationAnn-Kathrin Eisfeld, Sebastian Schwind, Kevin W Hoag, et al.
Oncotarget|October 27, 2016
The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanomaLorena P Suarez-Kelly, Gregory M Kemper, Megan C Duggan, et al.
Melanoma Research|May 23, 2019
Neuroblastoma RAS viral oncogene homolog mRNA is differentially spliced to give five distinct isoforms: implications for melanoma therapyMegan C Duggan, Kelly Regan-Fendt, Gonzalo N Olaverria Salavaggione, et al.
Frontiers in Immunology|June 30, 2023
Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapyChad Pickering, Paul Aiyetan, Gege Xu, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 10, 2013
A phase I trial of bortezomib and interferon-α-2b in metastatic melanomaJoseph Markowitz, Eric A Luedke, Valerie P Grignol, et al.
JCO Precision Oncology|June 7, 2021
Integrating Somatic and Germline Next-Generation Sequencing Into Routine Clinical Oncology PracticeJ Kevin Hicks, Rachel Howard, Phillip Reisman, et al.
Cancer Immunology, Immunotherapy : CII|February 7, 2019
A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanomaLorena P Suarez-Kelly, Kala M Levine, Thomas E Olencki, et al.
Pageof 9